-
Mashup Score: 1First-line osimertinib for lung cancer with uncommon EGFR exon 19 mutations and EGFR compound mutations - 7 hour(s) ago
Up to 20% of EGFR-mutated non-small cell lung cancer (NSCLC) cases harbor uncommon EGFR mutations, including atypical exon 19 and compound mutations. Relatively little is known about the efficacy of osimertinib in these cases.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 39
The available approved anti-cancer drugs for Chinese patients are relatively limited because of China’s low participation rate in international clinical trials. Therefore, a focus on approved anti-PD-1/PD-L1 drugs in China is needed. This study aims to assess the heterogeneity of anti-PD-1/PD-L1 antibodies manufactured in China (domestic PD-1/PD-L1) and overseas (imported PD-1/PD-L1) when combined with chemotherapy as the first-line treatment of NSCLC.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 57Immunotherapy with radiotherapy for brain metastases in non-small cell lung cancer patients:NEJ060 - 16 day(s) ago
Immune checkpoint inhibitor (ICI)-based treatment has become standard treatment for advanced non-small cell lung cancer (NSCLC) patients. We aimed to reveal the survival benefit of upfront radiotherapy for brain metastases (BMs) in NSCLC patients who received ICI alone (ICI-alone) or with chemotherapy (ICI-chemo).
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 23
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality worldwide. Specific genetic alterations, such as MET exon 14 (METex14) skipping, have been identified in NSCLC, allowing targeted therapy. Tepotinib, a highly selective MET inhibitor, has displayed promise in patients with advanced NSCLC. However, challenges arise when identifying treatment strategies for patients with discordant results regarding METex14 skipping detection between diagnostic tests.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 104
Responses to first-line PD-1 inhibition vary among patients with metastatic non-small cell lung cancer (NSCLC) and a PD-L1 TPS ≥50%. We previously reported improved clinical outcomes to first-line PD-1 inhibition in patients with metastatic NSCLC with a PD-L1 TPS of ≥90% vs 50-89% in a pilot study. Here, we report the three-year survival with first-line pembrolizumab and cemiplimab in two large independent cohorts of patients with PD-L1 TPS ≥90% vs 50-89% and characterize genomic and immunophenotypic differences between these PD-L1 expression groups, which were largely unknown.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 45Brief Report: Real-World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C-Mutated Non-Small Cell Lung Cancer - 2 month(s) ago
The KRAS G12C inhibitor sotorasib was approved for the treatment of advanced NSCLC in the second line or later based on the CodeBreaK100 trial. However, data on the real-world efficacy and safety of sotorasib, as well as its optimal dose, remain limited.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19Harnessing Opportunity: Pilot Intervention to Improve Lung Cancer Screening for Women Undergoing Breast Screening Mammography - 2 month(s) ago
The screening mammogram could be a “teachable moment” to improve lung cancer screening (LCS) uptake. The aim of our project was to combine patient self-referral with eligibility identification by providers as a two-pronged approach to increase rates of LCS among eligible women.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 61
MET proto-oncogene (MET) alterations are known driver oncogenes in non-small cell lung cancer (NSCLC). Since the identification of MET as a potential therapeutic target, extensive clinical trials have been performed. As a result, MET-targeted therapies, including MET tyrosine kinase inhibitors, monoclonal antibodies, and MET antibody–drug conjugates, now play important roles in the standard treatment of MET-altered NSCLC; they have considerably improved the outcomes of patients with tumors that harbor MET oncogenic drivers.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 97
The identification of genomic ‘targets’ through next-generation sequencing (NGS) of patient’s NSCLC tumors has resulted in a rapid expansion of targeted treatment options for selected patients. This retrospective study aims to identify the proportion of patients with advanced NSCLC in the Republic of Ireland whose tumours harbour actionable genomic alterations via broad NGS panel testing.
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 57Brief report: Long-term follow-up of adjuvant pembrolizumab following locally ablative therapy for oligometastatic non-small cell lung cancer. - 2 month(s) ago
Patients with oligometastatic non-small cell lung cancer (NSCLC) benefit from locally ablative therapies (LAT); the role of adjuvant systemic therapies, however, remains less clear. In a single-arm Phase II clinical trial, we demonstrated that patients with oligometastatic NSCLC treated with a year of pembrolizumab following LAT had superior progression free survival (PFS) compared to a historical control cohort. Herein, we present long term follow-up on PFS and overall survival (OS).
Source: www.jtocrr.orgCategories: General Medicine News, Hem/OncsTweet
Outcomes with first-line osimertinib in 37 pts with rare atypical #EGFR exon 19 or compound mutations in #JTOCRR @JTOonline from Dr. @SusanScottMD @tiacheunkarndee. RR 76%, median PFS 13m, time to discontinuation 22m, mOS 36m. https://t.co/SCiW2dsRqc